Literature DB >> 28689020

Ferulic acid supresses Th2 immune response and prevents remodeling in ovalbumin-induced pulmonary allergy associated with inhibition of epithelial-derived cytokines.

Alessa Sin Singer Brugiolo1, Ana Cláudia Carvalho Gouveia2, Caio César de Souza Alves3, Flávia Márcia de Castro E Silva4, Érick Esteves de Oliveira5, Ana Paula Ferreira6.   

Abstract

Asthma is characterized by intermittent airway obstruction and chronic inflammation, orchestrated primarily by Th2 cytokines. There is a strong rationale for developing new asthma therapies, since current treatment protocols present side effects and may not be effective in cases of difficult-to-control asthma. The purpose of this study was to evaluate the effect of ferulic acid, a phenolic acid commonly present in plants, in the ovalbumin-induced pulmonary allergy murine model.
METHODS: BALB/c mice were sensitized and challenged with ovalbumin, and treatments were provided by gavage. Six groups of mice (n = 6) were studied, labeled as: control, pulmonary allergy, dexamethasone, and 3 receiving ferulic acid (at 25, 50, and 100 mg/kg). Lung tissue, bronchoalveolar lavage fluid and serum were collected for analysis.
RESULTS: Ferulic acid treatment inhibited an established allergic Th2-response by decreasing the key features of pulmonary allergy, including lung and airway inflammation, eosinophil infiltration, mucus production and serum levels of OVA-specific IgE. These results were associated with lower levels of CCL20, CCL11 and CCL5 chemokines and IL-4, IL-5, IL-13, TSLP, IL-25 and IL-33 cytokines in lung tissue homogenate.
CONCLUSIONS: In this study it was demonstrated for the first time that ferulic acid treatment is able to suppress one of the main features of the airway remodeling, indicated by reduction of mucus production, besides the Th2 pathogenic response on ovalbumin-induced pulmonary allergy. Taken together, results shows that the immunopathological mechanism underlying these effects is linked to a reduction of the epithelial-derived chemokines and cytokines, suggesting that ferulic acid may be useful as a potential therapeutic agent for asthma.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Airway remodeling; Asthma therapy; Epithelial-derived cytokines; Ferulic acid; Ferulic acid (PubChem CID: 445858); Pulmonary allergy; Th2 immune responses

Mesh:

Substances:

Year:  2017        PMID: 28689020     DOI: 10.1016/j.pupt.2017.07.001

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  6 in total

1.  Leonurus sibiricus root extracts decrease airway remodeling markers expression in fibroblasts.

Authors:  J Wieczfinska; P Sitarek; T Kowalczyk; R Pawliczak
Journal:  Clin Exp Immunol       Date:  2020-07-18       Impact factor: 4.330

2.  Loop of Streptomyces Feruloyl Esterase Plays an Important Role in the Enzyme's Catalyzing the Release of Ferulic Acid from Biomass.

Authors:  Misugi Uraji; Haruka Tamura; Eiichi Mizohata; Jiro Arima; Kun Wan; Ken'ichi Ogawa; Tsuyoshi Inoue; Tadashi Hatanaka
Journal:  Appl Environ Microbiol       Date:  2018-01-17       Impact factor: 4.792

3.  Ferulic acid attenuates microglia-mediated neuroinflammation in retinal degeneration.

Authors:  Xiaowei Sun; Peng Sun; Limei Liu; Pengfei Jiang; Yuanbin Li
Journal:  BMC Ophthalmol       Date:  2021-01-06       Impact factor: 2.209

4.  Ferulic acid ameliorates lipopolysaccharide-induced tracheal injury via cGMP/PKGII signaling pathway.

Authors:  Xiaoyong Xie; Tong Yu; Yapeng Hou; Aixin Han; Yan Ding; Hongguang Nie; Yong Cui
Journal:  Respir Res       Date:  2021-12-04

Review 5.  Fermented Food in Asthma and Respiratory Allergies-Chance or Failure?

Authors:  Anna Dębińska; Barbara Sozańska
Journal:  Nutrients       Date:  2022-03-29       Impact factor: 5.717

6.  Nasal Epithelial Cells Activated with Alternaria and House Dust Mite Induce Not Only Th2 but Also Th1 Immune Responses.

Authors:  Seung-Heon Shin; Mi-Kyung Ye; Dong-Won Lee; Mi-Hyun Chae; Ba-Da Han
Journal:  Int J Mol Sci       Date:  2020-04-13       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.